Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: Iproceedings

Date Submitted: Jan 19, 2022
Date Accepted: Jan 19, 2022

The final, peer-reviewed published version of this preprint can be found here:

Adverse Events Following COVID-19 Immunization Reported Through Hotlines, February-August 2021, Bangladesh: Descriptive Study

Prince KTP, Billah MM, Khan FI, Alamgir A, Rahman M, Shirin T

Adverse Events Following COVID-19 Immunization Reported Through Hotlines, February-August 2021, Bangladesh: Descriptive Study

iproc 2022;8(1):e36636

DOI: 10.2196/36636

Adverse events following COVID-19 immunization reported through hotlines – February to August 2021, Bangladesh: A Descriptive study

  • Kyaw Thowai Prue Prince; 
  • Mallick Masum Billah; 
  • Farzana Islam Khan; 
  • ASM Alamgir; 
  • Mahbubur Rahman; 
  • Tahmina Shirin

ABSTRACT

Background:

For COVID-19 vaccine safety, the vaccination program of Bangladesh started facility-based passive surveillance to address adverse events following immunization (AEFIs) of COVID-19 vaccination. Institute of Epidemiology, Disease Control and Research (IEDCR), Bangladesh has been using emergency hotlines for outbreak reporting since 2008. During the COVID-19 pandemic, these hotlines are used for pandemic-related information and reporting. Thus, COVID-19 vaccinees also use these hotlines to report AEFIs.

Objective:

We analyzed the documented AEFIs records of IEDCR to characterize the vaccinees who reported AEFIs through IEDCR hotlines.

Methods:

We performed descriptive analysis of COVID-19 vaccinees who reported AEFIs through IEDCR hotlines from February to August 2021. We defined AEFIs as untoward medical occurrences which follow immunization and which do not necessarily have a causal relationship with the usage of the vaccines. We analyzed the vaccinees who reported AEFIs through IEDCR hotlines by age, gender, occupation, the severity of AEFIs, and time intervals of reporting.

Results:

Among 819 vaccinees who reported AEFIs through IEDCR hotlines, 68% (555/819) were male and their median age was 41 years (interquartile range: 32-51 years). Of them, 89% reported AEFIs following 1st dose of vaccination. Among females, 71% (186/264) were housewives. Among males, 45% (249/555) were service holders, 16% (90/555) were businessmen, 8% (46/555) were students. About 78% (638/819) of vaccinees were from urban vaccination centers. Vaccinees who had mild AEFIs like fever (62%), injection-site pain (41%), headache (25%) were reported through IEDCR hotlines. Although 65% (534/819) vaccinees who reported AEFIs through IEDCR hotlines developed symptoms within 24 hours of vaccination, only 24% (196/819) vaccinees reported them within 24 hours.

Conclusions:

Middle-aged, males, and urban vaccinees who developed mild AEFIs commonly reported AEFIs through IEDCR hotlines. We recommended that AEFIs data generated from different reporting systems including hotline numbers should be incorporated together for an efficient COVID-19 vaccine safety surveillance system.


 Citation

Please cite as:

Prince KTP, Billah MM, Khan FI, Alamgir A, Rahman M, Shirin T

Adverse Events Following COVID-19 Immunization Reported Through Hotlines, February-August 2021, Bangladesh: Descriptive Study

iproc 2022;8(1):e36636

DOI: 10.2196/36636

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.

Advertisement